PHILADELPHIA, Oct. 7, 2021 /PRNewswire/ — HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced that it has been awarded a contract with the Centers for Disease Control and Prevention (CDC) to provide a large-scale, fully interoperable, real-world dataset to advance a wide range of COVID-19 research, decision making, and public health impact objectives. Using privacy-preserving record linkage (PPRL), the HealthVerity data asset securely links de-identified patient-level data across medical and pharmacy claims, chargemaster, electronic medical records, and lab data, including genomic sequencing of COVID-19 variants, to generate comprehensive and longitudinal patient histories without sharing personally identifiable information.
The goal of this contract is to provide the CDC with a real-world dataset that is uniquely suited to provide novel insights into new and emerging priority questions related to SARS-CoV-2 variants, vaccinations, testing, re-infection, health impact, natural history, and the long-term effects of COVID-19. The data has high impact potential for CDC’s COVID-19 response and surveillance efforts because it offers CDC scientists the opportunity to conduct complex analyses and develop use cases on disease patterns, progression, and health outcomes. Leveraging its HealthVerity IPGE platform, including the nation’s largest privacy-protected healthcare and consumer data ecosystem, HealthVerity is assembling the largest, fully interoperable, real-world COVID-19 data asset ever acquired by the CDC.
HealthVerity is assembling the largest, fully interoperable COVID-19 data asset ever acquired by the CDCTweet this
“HealthVerity is proud to support the CDC in leveraging strategic data assets on its quest to understand the broad impact of COVID-19 on patients, healthcare systems, and communities,” said Andrew Kress, CEO at HealthVerity. “We are pleased that our expertise in patient identity resolution and privacy management combined with the broad cross-sectional healthcare and consumer data we manage on behalf of our data partners uniquely enables us to deliver a level of dimensionality for evidence generation that is critical to this major public health endeavor.”
In addition to COVID-19, the agreement provides the CDC with access to timely and comprehensive data on other key therapeutic areas such as viral hepatitis and HIV and the impact on key demographic groups, all in a privacy-protected, HIPAA-compliant manner.
HealthVerity has a history of serving key governmental health agencies to support public health initiatives. Most recently, HealthVerity supported the National Cancer Institute (NCI) for a groundbreaking study of SARS-CoV-2 antibodies in February 2021, announced a research contract with the U.S. Food and Drug Administration (FDA) to support COVID-19 clinical study and treatment opportunities in June 2020 and was awarded a PPRL contract for COVID-19 vaccine data with the Department of Health and Human Services (HHS) in November 2020.
About HealthVerity
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.
CONTACT: Katherine Epstein, kepstein@healthverity.com.